Malaysia

Reimbursed Care Access

Malaysia maintains a restrictive national framework for classical and novel psychedelics: most serotonergic/entheogenic compounds (psilocybin, MDMA, DMT, mescaline, 2C-X, 5‑MeO‑DMT, ibogaine, ayahuasca) are treated as controlled/illegal under national drug control policy with no authorized medical use outside approved research. Esketamine (SPRAVATO) is registered in Malaysia and is available through regulated medical channels; racemic/clinical ketamine is a controlled medicine used in clinical settings (largely as an anaesthetic and off‑label in individual private practices) but does not have broad public reimbursement for psychedelic/psychiatric indications.